

The University of Western Ontario
BIOLOGICAL AGENTS REGISTRY FORM
Approved Biohazards Subcommittee: July 8, 2011
Biosafety Website: www.uwo.ca/humanresources/biosafety/

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario (UWO) or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biological agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biological agents being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Electronically completed forms are to be submitted to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190 or to jstanle2@uwo.ca) for distribution to the Biohazards Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or biosafety@uwo.ca. If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: www.uwo.ca/humanresources/biosafety/.

Please ensure that all questions are fully and clearly answered. Failure to do so will lead to the form being returned, which will cause delays in your approval and frustration for you and your colleagues on the Committee.

If you are re-submitting this form as requested by the Biohazards Subcommittee, please make modifications to the form in bold print, highlighted in yellow. Please re-submit forms electronically.

PRINCIPAL INVESTIGATOR:	Dr. Derrick MacFabe
DEPARTMENT:	Psychology
ADDRESS:	Social Science Center 9244
PHONE NUMBER:	84703
EMERGENCY PHONE NUMBER(S):	519-282-9172 519-661-2111 X88176
EMAIL:	dmacfabe@uwo.ca

Location of experimental work to be carried out :

Building :	Social Science Centre	Room(s):	8238A
Building :	Social Science Centre	Room(s):	8225
Building :	Social Science Centre	Room(s):	8230 & 8205

***For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 15.0, Approvals).**

FUNDING AGENCY/AGENCIES: **GoodLife and Autism Research Institute**

GRANT TITLE(S): **The Role of Propionic Acid on Neuroplasticity and Behaviour in a Novel Rodent Model of Autism**

UNDERGRADUATE COURSE NAME(IF APPLICABLE): **N/A**

List all personnel working under Principal Investigators supervision in this location:

<u>Name</u>	<u>UWO E-mail Address</u>	<u>Date of Biosafety Training</u>
Francis Boon	fboon@uwo.ca	Jan/Feb 2010
Kelly Foley	kfoley	Jan/Feb 2010
Stacey Holbrook	sholbro@uwo.ca	reg. for Sept 2011
Lisa Tichenoff	lticheno@uwo.ca	Jan/Feb 2010

Please explain how the biological agents are used in your project and how they are stored and disposed of. The BARF without this description will not be reviewed.

The animals are held in the animal care facility in Social Science Center. The animals are perfused, decapitated and tissues that are being studied are removed for neuropathological and biochemical studies. The remainder of the body is frozen, then incinerated.

**Please include a ONE page research summary or teaching protocol in lay terms.
Forms with summaries more than one page will not be reviewed.**

PROJECT PURPOSE: To examine the role of the short chain fatty acid propionate, a common compound in the human diet and metabolism, and a major metabolic product of antibiotic resistant gut bacteria, on brain function and behaviour in a novel rodent model of autism.

EXPECTED BENEFIT: The development of a rodent model for ASD, using propionate (a food additive), and product of recently discovered autism associated gut bacteria, could be used to develop novel treatment strategies for ASD. The implications of food additives and common prenatal and childhood gut infections/antibiotic usage being involved in ASD makes its examination an important public health issue and potential basis for autism as a preventable/treatable neurometabolic disorder.

REASON FOR USING ANIMALS: Autism is a disorder of brain development, altered social behaviour movement and metabolism. Use of animals is absolutely essential to allow us to combine behavioural, biochemical, electrographic (EEG) and neuropathological data to gain valuable knowledge in understanding ASD at a whole body disorder at an animal level

REASON FOR USING SPECIES: Long Evans rats are an ideal choice because: 1)most extensively studied in brain development, physiology and behaviour 2) rapid development and large litter size (makes neonatal studies feasible), are sufficient size for EEG/biochemistry work, and 5)not "in bred" (serve as a useful model to study factors which effect human population). We are also using a series of established genetic mouse models of autism (Gabrb) to examine genetic environmental interactions in autism

1.0 Microorganisms

1.1 Does your work involve the use of biological agents? ☐ YES ☒ NO
(non-pathogenic and pathogenic biological agents including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA? ☐ YES ☐ NO

If YES, please give the name of the species

What is the origin of the microorganism(s)?

Please describe the risk (if any) of escape and how this will be mitigated:

Please attach the CFIA permit.

Please describe any CFIA permit conditions:

1.2 Please complete the table below:

Full Scientific Name of Biological Agent(s)* (Be specific)	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/Supplier	PHAC or CFIA Containment Level
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3
	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No			☐ 1 ☐ 2 ☐ 2+ ☐ 3

**Please attach a Material Safety Data Sheet or equivalent from the supplier if the bacterium used is not on this link:*
http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

Additional Comments:

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? ☐ YES ☒ NO
(If NO, please proceed to Section 3.0)

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	☐ Yes ☐ No		Not applicable
Rodent	☐ Yes ☐ No		
Non-human primate	☐ Yes ☐ No		
Other (specify)	☐ Yes ☐ No		

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Containment Level of each cell line	Supplier / Source of cell line(s)
Human	☐ Yes ☐ No			
Rodent	☐ Yes ☐ No			
Non-human primate	☐ Yes ☐ No			
Other (specify)	☐ Yes ☐ No			

**Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see www.atcc.org)*

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required ☐ 1 ☐ 2 ☐ 2+ ☐ 3

Additional Comments: _____

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? ☐ YES ☒ NO
If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/UNKNOWN	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid		☐ Yes ☐ Unknown		☐ 1 ☐ 2 ☐ 2+ ☐ 3
Human Blood (fraction) or other Body Fluid		☐ Yes ☐ Unknown		☐ 1 ☐ 2 ☐ 2+ ☐ 3
Human Organs or Tissues (unpreserved)		☐ Yes ☐ Unknown		☐ 1 ☐ 2 ☐ 2+ ☐ 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

Additional Comments: _____

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0? ☐ YES ☒ NO If NO, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done? ☐ YES, complete table below ☐ NO

Bacteria Used for Cloning *	Plasmid(s) **	Source of Plasmid	Gene Transformed or Transfected	Will there be a change due to transformation of the bacteria?	Will there be a change in the pathogenicity of the bacteria after the genetic modification?	What are the consequences due to the transformation of the bacteria?

* Please attach a Material Safety Data Sheet or equivalent if available.

** Please attach a plasmid map.

***No Material Safety Data Sheet is required for the following strains of *E. coli*:

http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

4.3 Will genetic modification(s) of bacteria and/or cells involving viral vectors be made?

☐ YES, complete table below ☐ NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results from transduction

* Please attach a Material Safety Data Sheet or equivalent.

4.3.1 Will virus be replication defective? ☐ YES ☐ NO

4.3.2 Will virus be infectious to humans or animals? ☐ YES ☐ NO

4.3.3 Will this be expected to increase the containment level required? ☐ YES ☐ NO

5.0 Will genetic sequences from the following be involved?

- ♦ HIV ☒ NO ☐ YES, specify
- ♦ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens ☒ NO ☐ YES, specify
- ♦ SV 40 Large T antigen ☒ NO ☐ YES
- ♦ E1A oncogene ☒ NO ☐ YES
- ♦ Known oncogenes ☒ NO ☐ YES, specify
- ♦ Other human or animal pathogen and or their toxins ☒ NO ☐ YES, specify

5.1 Is any work being conducted with prions or prion sequences? ☒ NO ☐ YES

Additional Comments: _____

6.0 Human Gene Therapy Trials

6.1 Will human clinical trials be conducted involving a biological agent? ☐ YES ☒ NO
(including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)
If no, please proceed to Section 6.0

6.2 If YES, please specify which biological agent will be used:
Please attach a full description of the biological agent.

6.3 Will the biological agent be able to replicate in the host? ☐ YES ☐ NO

6.4 How will the biological agent be administered?

6.5 Please give the Health Care Facility where the clinical trial will be conducted:

6.6 Has human ethics approval been obtained? ☐ YES, number: ☐ NO ☐ PENDING

7.0 Animal Experiments

7.1 Will live animals be used? ☒ YES ☐ NO If NO, please proceed to section 7.0

7.2 Name of animal species to be used **rat, mice**

7.3 AUS protocol # **2008-063**

7.4 Will any of the agents listed in section 4.0 be used in live animals
☒ NO ☐ YES, specify:

7.5 Will the agent(s) be shed by the animal:
☐ YES ☒ NO, please justify:

8.0 Use of Animal species with Zoonotic Hazards

8.1 Will any animals with zoonotic hazards or their organs, tissues, lavages or other body fluids including blood be used (see list below)? ☐ YES ☒ NO - If NO, please proceed to section 8.0

8.2 Will live animals be used? ☐ YES ☐ NO

8.3 If YES, please specify the animal(s) used:

♦ Pound source dogs	☐ YES	☐ NO
♦ Pound source cats	☐ YES	☐ NO
♦ Cattle, sheep or goats	☐ YES, species	☐ NO
♦ Non-human primates	☐ YES, species	☐ NO
♦ Wild caught animals	☐ YES, species & colony #	☐ NO
♦ Birds	☐ YES, species	☐ NO
♦ Others (wild or domestic)	☐ YES, specify	☐ NO

8.4 If no live animals are used, please specify the source of the specimens:

9.0 Biological Toxins and Hormones

9.1 Will toxins or hormones of biological origin be used? ☐ YES ☒ NO If no, please proceed to Section 9.0

9.2 If YES, please name the toxin(s) or hormones(s)
Please attach information, such as a Material Safety Data Sheet, for the toxin(s) used.

9.3 What is the LD₅₀ (specify species) of the toxin or hormone

9.4 How much of the toxin or hormone is handled at one time*?

9.5 How much of the toxin or hormone is stored*?

9.6 Will any biological toxins or hormones be used in live animals? ☐ YES ☐ NO

If YES, Please provide details:

*For information on biosecurity requirements, please see:

http://www.uwo.ca/humanresources/docandform/docs/healthandsafety/biosafety/Biosecurity_Requirements.pdf

Additional Comments: _____

10.0 Insects

10.1 Do you use insects? ☐ YES ☒ NO - If NO, please proceed to Section 10.0

10.2 If YES, please give the name of the species.

10.3 What is the origin of the insect?

10.4 What is the life stage of the insect?

10.5 What is your intention? ☐ Initiate and maintain colony, give location:
☐ "One-time" use, give location:

10.6 Please describe the risk (if any) of escape and how this will be mitigated:

10.7 Do you use insects that require a permit from the CFIA permit? ☐ YES ☐ NO
If YES, Please attach the CFIA permit & describe any CFIA permit conditions:

11.0 Plants

- 11.1 Do you use plants? ☐ YES ☒ NO - If **NO**, please proceed to Section 11.0
- 11.2 If YES, please give the name of the species.
- 11.3 What is the origin of the plant?
- 11.4 What is the form of the plant (seed, seedling, plant, tree...)?
- 11.5 What is your intention? ☐ Grow and maintain a crop ☐ "One-time" use
- 11.6 Do you do any modifications to the plant? ☐ YES ☐ NO
If yes, please describe:
- 11.7 Please describe the risk (if any) of loss of the material from the lab and how this will be mitigated:
- 11.8 Is the CFIA permit attached? ☐ YES ☐ NO
If **YES**, Please attach the CFIA permit & describe any CFIA permit conditions:

12.0 Import Requirements

- 12.1 Will any of the above agents be imported? ☐ YES, country of origin ☒ NO
If **NO**, please proceed to Section 12.0
- 12.2 Has an Import Permit been obtained from HC for human pathogens? ☐ YES ☐ NO
- 12.3 Has an import permit been obtained from CFIA for animal or plant pathogens? ☐ YES ☐ NO
- 12.4 Has the import permit been sent to OHS? ☐ YES, please provide permit # ☐ NO

13.0 Training Requirements for Personnel Named on Form

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS:

- ◆ Biosafety
- ◆ Laboratory and Environmental/Waste Management Safety
- ◆ WHMIS (Western or equivalent)
- ◆ Employee Health and Safety Orientation

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biological agents in Sections 1.0 to 9.0 have been trained.

An X in the check box indicates you agree with the above statement... ☒
Enter Your Name Dr. Derrick MacFabe **Date:** Aug 30/2011

14.0 Containment Levels

14.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required. ☒ 1 ☐ 2 ☐ 2+ ☐ 3

14.2 Has the facility been certified by OHS for this level of containment?

☐ YES, location and date of most recent biosafety inspection:

☐ NO, please certify

☒ NOT REQUIRED for Level 1 containment

14.3 Please indicate permit number (not applicable for first time)

BIO-UWO-0223

15.0 Procedures to be Followed

15.1 Are additional risk reduction measures necessary beyond containment level 1, 2, 2+ or 3 measures that are unique to these agents? ☐ YES ☒ NO

If YES please describe:

Typo

15.2 Please outline what will be done if there is an exposure, needlestick injury or an accidental splash:

Animal Bites: Educate persons working with animals that all animal bites are potentially serious and require immediate First Aid. The wound should be washed immediately with warm soapy water. If bleeding, attempt to encourage bleeding by gently expressing the wounded area. After washing, cover the wound with a dry sterile dressing, Go to Workplace health Rm. 25, UCC for further assessment.

15.3 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.shs.uwo.ca/workplace/newposition.htm>

An X in the check box indicates you agree with the above statement... ☒

Enter Your Name Dr. Derrick MacFabe **Date:** Aug 29, 2011

15.4 Additional Comments: _____

16.0 Approvals

1) UWO Biohazards Subcommittee:

SIGNATURE: _____

Date: _____

2) Safety Officer for the University of Western Ontario

SIGNATURE: _____

Date: _____

3) Safety Officer for Institution where experiments will take place (if not UWO):

SIGNATURE: _____

Date: _____

Approval Number: _____ Expiry Date (3 years from Approval): _____

Special Conditions of Approval: